Appendix 2: Example Weekly Newsletter From

Sent: Friday, October 04, 2002 2:10 PM
Subject: weekly newsletter

Can't read the following email? Want a plain text version? Click here and all future newsletters will be sent to you in plain text. If the link is not active, you can send your request to

October 4, 2002


Implementing a critical pathway based on the ACC/AHA guidelines

Accredited by the Duke University School of Medicine: .75 hour, category 1
Drs Paul W Armstrong, Christopher P Cannon, Christopher B Granger, and Matthew T Roe discuss the design and implementation of an ACS critical pathway based on the ACC/AHA guidelines for NSTEMI.
[Supported by an unrestricted educational grant from Aventis Pharmaceuticals]

New approaches to the prevention of atherothrombotic events in patients with vascular disease

CME credit: 1 hour, category 1
Dr Christopher Cannon chairs a discussion with Drs Donald Easton, William Hiatt, and Matthew Roe about emerging data supporting primary and secondary prevention strategies for vascular disease.
[Supported by an unrestricted educational grant from Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.]


Decreasing risk and optimizing outcomes in patients with diabetes
A series of online educational programs designed to help physicians manage these high-risk patients. Drs Deepak L Bhatt, Darren McGuire, and Steve Marso review the clinical data, consider current reports, and describe their approaches to intervening in coronary artery disease when the problem is compounded by diabetes. Printable, full-text available.
[The programs are provided by the Institute for Continuing Healthcare Education and Conceptis Technologies and are supported by an educational grant from Eli Lilly and Company.]


Visit,a website for healthcare professionals, for the latest news on stroke and arterial vascular disease. Registration is free.


Assay-guided abciximab bolus dosing worked, saved money in registry study
Giving only 70% of the standard abciximab bolus before PCI, as long as a rapid assay says platelet suppression is adequate, is safe and effective as well as cheaper overall, according to a prospective registry analysis. (Transcatheter Cardiovascular Therapeutics 2002.) [Oct 3]

Judge grants permanent injunction of Guidant-Cook stent data

With an injunction preventing the use of information, data, or technology generated or gathered in connection with the agreements between Guidant and Cook Inc on paclitaxel-coated stents, Boston Scientific now looks poised to be the second drug-eluting stent to reach the market, in light of the recent TAXUS data. [Oct 2]

Time to stop measuring the ejection fraction in heart failure patients?

Dr Marvin Konstamargues forcefully—and colorfully—that relying too heavily on EF measurements leads to inappropriate patient management. But if EF is abandoned, what can be used in its stead? (Heart Failure Society of America's 6th Annual Scientific Meeting.) [Oct 1]

RESCUT and REDUCE II cast doubt on Cutting Balloon's major niche
The razor-fitted Cutting BalloonTM is used at many centers to treat in-stent restenosis, but 2 randomized trials have questioned whether it's any better than the standard balloon for that indication. (Transcatheter Cardiovascular Therapeutics 2002.) [Oct 1]

Oral sirolimus-type drugs preferable to coated stents?

The clinical trial results with drug-coated stents have been overblown, and more long-term data are needed before investing the significant sums necessary for routine use of these devices, an expert says. Circulation [Oct 1]

Eplerenone gets FDA approval for hypertension

Pharmacia's selective aldosterone blocker is a potential blockbuster that has been described as a "cleaner, safer" version of spironolactone. [Sep 30]

Can statins cause chronic low-grade myopathy?

The development of muscle symptoms without raised creatinine kinase levels associated with the use of statins in 4 patients has led to calls for more research on the mechanism by which these drugs induce myopathy. Ann Intern Med [Sep 30]

TAXUS II: 6-month data show significant benefits of paclitaxel-eluting stents
A new study comparing bare stents with either slow- or moderate-release paclitaxel stents shows the drug-eluting stents reduced restenosis, as well as clinical end points, without any significant advantage of one formulation over the other. (Transcatheter Cardiovascular Therapeutics 2002.) [Sep 27]


Do you think heart failure patients with normal EF should receive the same drugs as patients with low EF?

Read Time to stop measuring the ejection fraction in heart failure patients? and cast your vote at the bottom of the right-hand column.


Do you think that most PCI patients should receive (if available) a sirolimus-eluting stent ?

A majority—73%—of the voters said yes. The votes were cast following the publication of the story SIRIUS final results show 3.2% in-stent, 8.9% in-segment restenosis rates with sirolimus-eluting stents.

Logon help

If you encounter problems accessing the site, technical help is available by phone Monday to Friday from 9:00 am to 5:00 pm ET: 1.888.330.8193 (toll-free in the US and Canada) or +1.514.931.2998.
You can also reach us at

Don't want mail?

If you want to be removed from this mailing list, click here.

© 2002